header logo image


Page 1,078«..1020..1,0771,0781,0791,080..1,0901,100..»

The dangers of AMD; disease can cause blindness if left untreated … – KHON2

February 6th, 2017 9:45 am

It strikes like a thief in the night.

The disease, if left untreated, can slowly steal your central vision, leaving you blind for the rest of your life.

Age-related macular degeneration (AMD) affects more than 10 million people in the U.S.

This is the most common cause of vision loss that is not correctable by lenses or cataract surgery, and is very common in the 80-plus group. Fifty percent of my patients have that disease, said ophthalmologist Dr. Malcolm Ing. That occurs at the back of the eye, right near the optic nerve, right where my finger is. That is the macular, and that is the area that deteriorates.

Patients may notice blacking or graying out at the central part of their vision while reading.

Patients with dry AMD receive antioxidants as treatment.Those with Wet AMD are at higher risk of going blind and must receive injections directly into the eyes every six weeks.

Its a downhill slide right away if you see hemorrhages in the macular, Ing said. If left untreated, you can go blind within a week.

One way to avoid this is to not smoke.

For instance, if you smoke, you have four times the incidents four times 400 percent increase in macular degeneration, Ing explained.

Controlling your weight also helps.

We found that you have a big opu, like some of the people have in our kupuna group, then you increase your incidents by 200 percent, so twice as likely to have that problem, Ing said.

Belly fat produces inflammatory chemicals that target our eyes and brain. Eating fish can reduce risk of AMD by 40 percent, and so can eating green leafy vegetables.

Eat your spinach, because it has green leafy vegetables, and green leafy vegetables has nutrients that help protect the retina, Ing said.

February is AMD Awareness Month, another reason to see your eye doctor regularly.

Click here for more information about AMD from the National Eye Institute.

Go here to read the rest:
The dangers of AMD; disease can cause blindness if left untreated ... - KHON2

Read More...

Malin stakes 32% take in US biotechnology company Artizan – Irish Times

February 6th, 2017 9:45 am

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota.

Irish based life sciences company Malin said on Monday that it has acquired a 32 per cent shareholding of US biotechnology company Artizan Biosciences.

Dublin-based Malin, which has invested more than 300 million in life sciences companies since it was established in early 2015, invested in Artizan via a founding equity round alongside Hatteras Venture Partners, a venture capital firm with which Malin has a strategic partnership.

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota. It was spun out of Yale University and established as a standalone business in 2016 and its founders include Prof. Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD, from Yale University. Artizan, which aims to be a leader in the microbiota-driven inflammatory diseases space, has developed a capability of distinguishing certain pathogenic bacteria from the remainder of the intestinal microbiota. The ability to target these specific bacteria could lead to treatment options for any number of digestive disorders as well as other diseases including obesity, autoimmune disease and a wide variety of skin, lung and central nervous system (CNS) diseases.

Artizans proposed approach is disruptive to current treatment and would offer new and novel therapeutic options for patients suffering from a broad array of inflammatory disorders, Adrian Howd, chief investment officer of Malin, said.

Last month Malin acquired a 33 per cent shareholding of Wren Therapeutics, a newly created biopharmaceutical company based in Cambridge, UK. It was set up by a number of former Elan executives in 2015.

Read more from the original source:
Malin stakes 32% take in US biotechnology company Artizan - Irish Times

Read More...

Opinion: Harry Boxer: Watch these two biotechnology stocks – MarketWatch

February 6th, 2017 9:45 am

President Trump pressed Big Pharma executives to increase U.S. production and lower drug prices.

As biotechnology stocks have been showing momentum following a meeting between President Trump and pharmaceutical executives Tuesday, our two long investments to watch are in that sector. There are also several shorts among our charts to watch to play the potential downside in this near-term, toppy-looking stock market.

Gene-therapy company bluebird bio Inc. BLUE, -2.10% has a strong-looking chart. The stock recently broke out of a wedge pattern, in which its price range had narrowed for two months in essentially a sideways direction. The stock continued the upmove on Tuesday when it popped $5.90, or over 8%, to $74.50, and followed through for another $1.10 on Wednesday to $75.60. The stock is now positioned to challenge its recent high at $79.70 from early December. A break through there could lead to a move into the mid-$80s, followed by a next target in the mid-$90s. With short interest of 9.2 its average volume, the price advance could be further fueled by short covering.

Cara Therapeutics Inc. CARA, -0.90% a cannabis-based biotech, has been steadily climbing since the start of the year. On Wednesday, the stock popped $1.17, or 7.6%, to $16.49 on 4.7 million shares, which is huge volume for this stock, the biggest since mid-November. The stock got as high as $17.20 intraday before pulling back into the close. It is a bit extended near the top of its channel and could pull back and consolidate before its next move, but momentum could carry it a bit further toward $18.

On the short side, Carters Inc. CRI, +0.26% continues lower since its July 2016 top above $112. On Wednesday, shares in the childrens wear retailer were down another $1.05, or 1.3%, to $82.70, on 690,100 shares traded. The stock appears headed toward the bottom of its declining channel in the $73-$74 range.

Signet Jewelers Ltd. SIG, -0.67% is also continuing lower. The stock rallied from the bottom of its declining price channel to the top in the last quarter of 2016, but has since broken down. Shares fell another 66 cents to $77.01 on 1.5 million shares traded on Wednesday. Watch for a test of the late-September low in the $72-$73 range. A takeout of that could drop the stock near its channel bottom in the low- to mid-$60s.

See Harrys video chart analysis on these and other stocks.

The writer has no holdings in any securities mention in this article.

Harry Boxer is the founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis and live chart presentations.

Follow this link:
Opinion: Harry Boxer: Watch these two biotechnology stocks - MarketWatch

Read More...

Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil – National Catholic Register

February 6th, 2017 9:45 am

Commentary | Feb. 3, 2017

Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil

Should Christians face unethical uses of biotechnology with despair and resignation or with hope and determination?

Ive spent the last decade writing and speaking about the remarkable and terrifying world of biotechnology from a Catholic perspective. Many times Ive felt like Frodo Baggins at the gates of Mordor, looking upon Mt. Doom with despair and dread.

Ive never felt this more acutely than in the past few months. A series of recent headlines have renewed my sense of hopelessness in the face of the never-ending assault on the dignity of human life by modern biotechnology.

The gloom began to settle when it was revealed that a Swedish scientist is editing the DNA of healthy human embryos.Fredrik Lanner,a developmental biologist, is using a new gene-editing technique called CRISPR to disable some genes in healthy human embryos to see how those genes affect development. He and his team are intentionally modifyingotherwise healthy IVFembryos so they cannot develop properly.

Anin-depth story byNPRreveals that while the reporter was observing thegeneticmanipulation of five donated IVF embryos, one didnt survive the thawing process and one perished after being injected with the experimental gene-editing tool. Of the three who survived, one continued to divide, but not for long.All of the embryos were to be destroyedbefore they are 15 days old,as the law in Sweden dictates. Lanner insists that his research is critical to understanding human development, which, in turn, will shed light on infertility and disease.

Lanners work makes many ethicists and scientists extremely nervous. Jennifer Doudna, the co-inventor of CRISPR, along with other heavy-hitting scientists,havecalled for a voluntary moratorium on any editing of human embryosfor fear that it will lead to the creation of genetically modified children. Marcy Darnovsky, of the left-leaning Center for Genetics and Society, explains why she and her group havebeen so vocal in their opposition to the modification of human embryos. She told NPR: The production of genetically modified human embryos is actually quite dangerous. ... When youre editing the genes of human embryos, that means youre changing the genes of every cell in the bodies of every offspring, every future generation of that human being. So these are permanent and probably irreversible changes that we just dont know what they would mean.

Then came the revelation that a U.S. doctor traveled to Mexico to create the first baby intentionally engineered to have three genetic parents. This technique, misnamed mitochondrial replacement or MR, seeks to eliminate the transmission of genetic disease through the mitochondria.Mitochondria are small but abundant organellesoutside the nucleusinthe cytoplasmof our cells that make energy. They have their own DNA called mtDNA. We inherit our mtDNA solely from our mothers. A woman who carries a deleterious mutation in her mtDNA cannot help but pass that on to her offspring.

There are various MR techniques that replace the mitochondria of a woman with mitochondrial disease with the mitochondria of a donor femalein the IVF process.Essentially, MR creates a genetically alteredembryo with the genetic material from three people, one man and two women.

MR had only undergone limited study in primates before getting approval in the United Kingdom for use in fertility clinics to make babies. Little is known about the complexcommunication between the DNA in the nucleus and the DNA in the mitochondria,and so there is little data on the effects ofa mismatch between the nuclear DNA and mtDNA.

Alsoin all MR, its the nucleus thats being moved from cell to cell, not the mitochondria which is why mitochondrial replacement is such a misnomer.This makes MR acousin to cloning, which also transplants the nucleus of one cell into anotherto make a new organism. MR brings with it many of the same risks.Scientists are concerned about the health of the resulting children.

In anopen letterto the U.K. Parliament, Dr. Paul Knoepfler, a vocal American stem-cell researcher, warned: Even if, hypothetically, this technology might help avoid some people from having mitochondrial disorders (and thats a big if), the bottom line is that there is an equal or arguably greater chance that it will tragically produce very ill or deceased babies.

MRis also a germ-line genetic modification, which means that any girl born with this technique will pass her genetic modification on to her children.

A recent review in Nature reveals that MR leaves a tiny percentage of mutant mitochondria behind, and sometimes the mutant mitochondria rapidly divide and overtake the healthy mitochondria. Shoukhrat Mitalipov, head of the Center for Embryonic Cell and Gene Therapy at the Oregon Health and Science University, reported a 15% failure rate where mitochondrial defects returned. Mitalipov told NPR, That original, maternal mitochondrial DNA took over, and it was pretty drastic. There was less than 1% of the original maternal mitochondrial DNA present after replacement with donor DNA and before fertilization, and yet it took over the whole cell later. University of California San Francisco professor Patrick OFarrell suggests that mutant mitochondria can resurge at any time in a developing three-parent child or even resurface in future generations.

For all these reasons, MR is not yet approved by the FDA in the United States,and may never be.So, when a Jordanian woman with mitochondrial disease wanted to have a child using MR, John Zhang, from the New Hope Fertility Center in New York City, had to perform the procedure in Mexico. He created five embryos,and, according toNewScientist.com,only one developed normally. That child is now 9 months old.

Zhang went to Mexico because, he said, there are no rules, and yet he insists he did the safe and ethical thingin the absence of any medical or ethical oversight. In an ironic twist, the couple is Muslim and so chose the MR technique that wouldnt destroy existing embryos.But it was clear that only male embryos would be transferred for gestation, because boys cant pass on the genetic modification. What happened to the other four embryos, however? Were they destroyed,discarded or frozen? If they were females, would they have been destroyed anyway to make sure they couldnt pass on any ill effects?

Darnovskycalledthis rogue experimentationand added, No researcher or doctor has the right to flout agreed-upon rules and make up their own. This is an irresponsible and unethical act.

Knoepflerrespondedto the news by remindingus that this is a living human experiment that is going to unfold over years and decades. It is also worth noting that this child is a genetically modified human being as a result of this technique.

Of course, these are happenings to despair of not only because of the sheer disregard for the sanctity of individual human lives, but because of the breakneck speed at which scientists are kicking ethical lines farther and farther down the road like a tin can. All the while, they insist that its for the good of humanity. I wonder: How can wetreatindividual members of the human species so callously and then, at the same time, say its for the good of the whole human race?

I fear there is no line we wont cross;no ethical boundary wewonttear down in the name of science.

On a daily basis, Im surrounded by science and scientists. Often, their response to this madness is that its going to happen anyway, and theres no way to stop it, which implies we must go along to get along all in the name of progress.

If I am Frodo, then they and the rest of society are Saruman giving in to the despair and making a deal with Sauron.In the film version of The Lord of the Rings, Saruman says to Gandalf: Against the power of Mordor there can be no victory. We must join with him, Gandalf. We must join with Sauron. It would be wise, my friend.

Gandalf replies, Tell me, friend, when did Saruman the Wise abandon reason for madness?

Indeed. When did science abandon reason for madness, ethics for recklessness?

So what shall we do? If wesuccumb to despair, we become like Saruman.

We always have prayer. Its time toadd human embryonic research and germ-line human genetic engineering to our list of life issues that we pray about.It doesnt matter whether we understand the finer points of the science or not.Praying for an end to abortion andassisted suicide is nolongerenough.

In addition to prayer, there are other things we can do. The first is to vote pro-life at every level of government, from city council to state assemblymen. Being pro-life isnt just about abortion, however. Its about protecting the sanctity of life from the beginning to the end. Pro-life legislators, even if they cannot overturn Roe v. Wade, can effect local and state laws and steer funding away from unethical research.

Secondly, we must fight for conscience rights for medical professionals. I envision a not-so-far-off world wheredoctorsare forced into making genetically engineered embryos and bringing these children to term simply because parents claim its their reproductive right to have the children of their design. Without conscience rights, unethical experimentation on the next generation will be rampant and unchecked.

We must, however, always have hope. Whenstaring downthe juggernaut that is modern biotechnology, I always remember Frodo Baggins.When he was faced with the seemingly impossible task of taking the One Ring to Mordor, instead of shying away because it was too hard, he said: I will take the Ring, though I do not know the way.

Rebecca Tayloris a

clinical laboratory specialist in molecular biology.

She writes about bioethics on her blog,Mary Meets Dolly.

Excerpt from:
Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil - National Catholic Register

Read More...

More Volatility Ahead for Biotechnology Sector – Wall Street Journal (blog)

February 6th, 2017 9:45 am
More Volatility Ahead for Biotechnology Sector
Wall Street Journal (blog)
After underperforming the S&P 500 over the past six months, the biotechnology sector is poised for more volatility ahead. The group drew plenty of attention on the campaign trail as both and Democratic candidate criticized the high prices for drugs ...

Link:
More Volatility Ahead for Biotechnology Sector - Wall Street Journal (blog)

Read More...

Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) – The Independent Republic

February 6th, 2017 9:45 am

Intrexon Corporation (XON) ended last trading session with a change of 5.25 percent. It trades at an average volume of 1.33M shares versus 1.7M shares recorded at the end of last trading session. The share price of $22.04 is at a distance of 8.09 percent from its 52-week low and down -45.23 percent versus its peak. The company has a market cap of $2.61B and currently has 118.35M shares outstanding. The share price is currently -5.82 percent versus its SMA20, -16.17 percent versus its SMA50, and -17.92 percent versus its SMA200. The stock has a weekly performance of 2.04 percent and is -9.3 percent year-to-date as of the recent close.

Jan. 26, 2017 Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (XON) committed to enabling the study of life-threatening human diseases, has been awarded a subcontract to create genetically engineered miniswine models of sickle cell disease as part of a national resource that could lead to new treatments for the disorder.

The subcontract is with Leidos Biomedical Research, Inc., prime contractor for the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, part of the National Institutes of Health (NIH). Work under the subcontract will support the NIHs National Center for Advancing Translational Sciences (NCATS) in creating genetically engineered miniswine models of sickle cell disease. Exemplar Genetics will develop several versions of genetically engineered miniswine models of sickle cell disease that more accurately replicate the human pathology as compared to traditional research models.

Keryx Biopharmaceuticals, Inc. (KERX) recently recorded -0.55 percent change and currently at $5.45 is 75.24 percent away from its 52-week low and down -30.13 percent versus its peak. It has a past 5-day performance of 13.54 percent and trades at an average volume of 1.61M shares. The stock has a 1-month performance of -12.38 percent and is -7 percent year-to-date as of the recent close. There were about 106.55M shares outstanding which made its market cap $580.7M. The share price is currently -1.7 percent versus its SMA20, -5.27 percent versus its SMA50, and -1.49 percent versus its SMA200.

Nov. 18, 2016 Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced case study data, which showed that Auryxia (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. These data were presented in a poster presentation at the American Society of Nephrologys 2016 Kidney Week taking place in Chicago.

The rest is here:
Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) - The Independent Republic

Read More...

2 Sizzling Hot Biotechnology Stocks: Achillion Pharmaceuticals, Inc. (ACHN), Stemline Therapeutics, Inc. (STML) – The Independent Republic

February 6th, 2017 9:45 am

Achillion Pharmaceuticals, Inc. (ACHN) ended last trading session with a change of 2.61 percent. It trades at an average volume of 2.22M shares versus 1.78M shares recorded at the end of last trading session. The share price of $4.32 is at a distance of 14.29 percent from its 52-week low and down -57.06 percent versus its peak. The company has a market cap of $575.38M and currently has 133.19M shares outstanding. The share price is currently 2.99 percent versus its SMA20, 3.06 percent versus its SMA50, and -38.89 percent versus its SMA200. The stock has a weekly performance of 5.62 percent and is 4.6 percent year-to-date as of the recent close.

On Dec. 28, 2016 Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), related to enrollment in the OMEGA-1 Phase 2b global, clinical trial of JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335 in patients with treatment-naive chronic hepatitis C virus infection (HCV) without cirrhosis.

We are delighted to have reached this milestone following Janssens recent initiation of the OMEGA-1 global clinical trial evaluating JNJ-4178, a once-daily combination of AL-335, simeprevir, and the Achillion-discovered NS5A inhibitor, odalasvir, and we look forward to JNJ-4178s continued clinical advancement, commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion.

Stemline Therapeutics, Inc. (STML) recently recorded 16.96 percent change and currently at $6.55 is 68.81 percent away from its 52-week low and down -55.14 percent versus its peak. It has a past 5-day performance of -35.78 percent and trades at an average volume of 285.02K shares. The stock has a 1-month performance of -44.96 percent and is -38.79 percent year-to-date as of the recent close. There were about 20.21M shares outstanding which made its market cap $132.38M. The share price is currently -41.5 percent versus its SMA20, -44.82 percent versus its SMA50, and -29.73 percent versus its SMA200.

Feb. 02, 2017 Stemline Therapeutics, Inc. (STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, provides an update on its ongoing pivotal Phase 2 trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN), using Stemlines experimental compound, SL-401. BPDCN at present has no approved treatment.

On January 18, the Company received a report that a patient death had occurred. The patient had developed capillary leak syndrome (CLS), a known, sometimes fatal, and well-documented side effect of SL-401. The cause of the patients death has not yet been determined. The safety profile for SL-401 includes CLS, and there have been previous deaths reported in patients with CLS in this trial, which have been disclosed in public presentations. That CLS is an expected complication of the administration of SL-401 has also been identified in filings with the Securities and Exchange Commission (SEC) and U.S. Food and Drug Administration (FDA), as well as in the studys informed consent forms and other information provided to investigators.

See the article here:
2 Sizzling Hot Biotechnology Stocks: Achillion Pharmaceuticals, Inc. (ACHN), Stemline Therapeutics, Inc. (STML) - The Independent Republic

Read More...

Two Biotechnology Names Are Hot: Celldex Therapeutics, Inc. (CLDX), Eleven Biotherapeutics, Inc. (EBIO) – The Independent Republic

February 6th, 2017 9:45 am

Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of 2.08 percent. It trades at an average volume of 2.28M shares versus 1.33M shares recorded at the end of last trading session. The share price of $3.43 is at a distance of 20.35 percent from its 52-week low and down -60.8 percent versus its peak. The company has a market cap of $340.19M and currently has 99.18M shares outstanding. The share price is currently -2.15 percent versus its SMA20, -7.49 percent versus its SMA50, and -13.68 percent versus its SMA200. The stock has a weekly performance of 1.48 percent and is -3.11 percent year-to-date as of the recent close.

On Dec. 14, 2016 Celldex Therapeutics, Inc. (CLDX) announced the appointment of Gerald McMahon, Ph.D., to the Companys Board of Directors. Dr. McMahon was previously the President and Chief Executive Officer of Kolltan Pharmaceuticals. In addition, the Company announced that Richard van den Broek has resigned from the Board due to increasing responsibilities in other endeavors.

Dr. McMahon brings an exceptional background in science and drug development, particularly in the oncology space, to the Celldex Board, said Larry Ellberger, Chairman of the Board of Directors at Celldex Therapeutics. We believe he will be a valuable addition as we advance a robust pipeline, which now also includes drug candidates targeting receptor tyrosine kinases, an area of expertise for Jerry. I would also like to recognize Rich for his contributions to Celldex. We wish him all the best in his future endeavors.

Eleven Biotherapeutics, Inc. (EBIO) recently recorded 4.61 percent change and currently at $2.27 is 804.38 percent away from its 52-week low and down -61.98 percent versus its peak. It has a past 5-day performance of 4.13 percent and trades at an average volume of 1.15M shares. The stock has a 1-month performance of -1.73 percent and is 18.85 percent year-to-date as of the recent close. There were about 23.17M shares outstanding which made its market cap $52.6M. The share price is currently 5.56 percent versus its SMA20, 4.83 percent versus its SMA50, and -9.19 percent versus its SMA200.

On November 14, 2016 Eleven Biotherapeutics, Inc. (EBIO) reported financial results for the third quarter ended September 30, 2016, and recent business highlights.

This is an exciting period for Eleven. We completed the Roche licensing deal, including $30 million in upfront and milestone payments received to date. We also completed the acquisition of Viventia Bio Inc. which allowed us to become a late-stage oncology company. Perhaps most excitingly, we are making significant progress in moving forward what we believe could be therapeutics that materially improve patients lives. We anticipate complete enrollment in the first half of next year for our Phase 3 clinical trial of Vicinium as a potential treatment for high-grade non-muscle invasive bladder cancer, and expect topline data in the first half of 2018, said Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics. We also plan to initiate our Phase 2 trial in late-stage squamous cell carcinoma of the head and neck with Proxinium in combination with a checkpoint inhibitor in the first half of 2017. Also in 2017, we plan on submitting an IND with the FDA for our lead product in our systemic pipeline based on our proprietary payload deBouganin. With the combined expertise of Eleven and the Viventia team, I am very excited about the opportunities we have ahead.

Go here to read the rest:
Two Biotechnology Names Are Hot: Celldex Therapeutics, Inc. (CLDX), Eleven Biotherapeutics, Inc. (EBIO) - The Independent Republic

Read More...

Rheumatoid arthritis and feet: The connection and feet arthritis pain relief tips – Bel Marra Health

February 6th, 2017 9:44 am

Home Anti-Aging Arthritis Rheumatoid arthritis and feet: The connection and feet arthritis pain relief tips

Rheumatoid arthritis is a chronic disease involving the immune system, in which joints undergo inflammation. causing pain and stiffness.People with rheumatoid arthritis generally find difficulty performing simple movements that involve the joints, such as walking, standing up, and sitting down.

This condition has also affected individual performance at work or school, prompting the medical field to identify an effective treatment. Having this inflammatory condition affecting the joints may also be responsible for certain emergency visits to the hospital, especially when a person suffers from a decreased ability to operate a motor vehicle or machine. In other cases, visits to the emergency room may be due to extreme pain experienced by a patient with rheumatoid arthritis.

Common treatment plans for rheumatoid arthritis include anti-inflammatory drugs, such as aspirin, ibuprofen, and naproxen. It is also possible to prescribe disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis, although this type of treatment may also increase the risk of developing severe side effects, which may also require emergency medical attention. More recent improvements in treatment include the use of biologics, which are proteins that influence the immune system to slow down the progression of rheumatoid arthritis.

In extreme cases of rheumatoid arthritiswhere drug treatment appears to be ineffectivesurgery may also be recommended. It is important to understand that this disorder involves the immune system and the joints, and may also decrease the ability of a person to move. Many emergency calls involving the elderly are caused by rheumatoid arthritis increasing slips and falls.

Based on the severity of rheumatoid arthritis and its association with emergency medical treatments caused by accidents, health groups and researchers have looked into specific signs and symptoms that could be detected at an early stage. Using this information, people who are at a higher risk of developing rheumatoid arthritis may be educated on how to maintain their healthy bodies at an earlier age and possibly prevent the development of this immune system-related inflammatory disease. This information may also decrease the incidence of emergency visits to the hospital and ultimately lower the need for aggressive treatment of the disease.

According to a recent medical report, the features of the feet may serve as a reliable indicator for signs of rheumatoid arthritis at its early stages and the condition of an individuals immune system. For example, the ankle is composed of several joints and generally responsible for the stability of the body while standing upright. Any signs of stiffness, swelling, and pain in the ankle may indicate that this foot area may need emergency treatment in order to prevent further deterioration.

The report presented the findings of 100 individuals with rheumatoid arthritis who were interviewed during their earlier stages of the disease. The results of the study showed that the earliest symptoms of foot problems involved the ankle, followed by the forefoot. Years after, these individuals also experienced pain and stiffness in the hindfoot and midfoot. The study participants also admitted that they used insoles as primary treatment of the pain they encounter in their feet. The report also showed that aside from early foot problems, these patients also presented higher body weight, so it is possible that the rheumatoid arthritis development was faster due to this specific feature.

This recent medical report provides direct proof that certain foot features could serve as indicators of rheumatoid arthritis.

Below are some tips that may help you manage foot pain caused by arthritis. Be sure to check with your doctor before making any changes to your pain relief regimen.

Visit your doctor: The first step in seeking pain relief should always be to see your doctor to obtain a proper diagnosis. Your family doctor can refer you to a podiatrist or rheumatologist, who will check your feet annually to look for signs of arthritis and evaluate if any medications or exercise regimens are working.

Pick the right shoes: Ensure that your shoes have arch support, are wide enough for your feet, and are comfortable enough to minimize any pain you may feel. Toning athletic shoes with rocker bottoms are a good choice for a supportive, comfortable shoe.

Stretch: Stretching your Achilles tendons, along with the tendons in the balls of your feet and toes, can help improve joint mobility and relieve pain.

Get a foot massage: A foot massage that focuses on the balls of your feet and your toes can help relax the muscles in your feet and provide pain relief.

Topical ointments: Ointments that contain capsaicin can help reduce inflammation when applied topically to problem areas. Try using one of these creams or ointments on your feet for arthritis pain relief.

Related: Rheumatoid arthritis (RA): Causes, symptoms, and treatment

Related Reading:

Rheumatoid arthritis patients are at a higher risk for heart failure: Study

Rheumatoid arthritis and skin problems: Causes and treatment

See the original post:
Rheumatoid arthritis and feet: The connection and feet arthritis pain relief tips - Bel Marra Health

Read More...

Local woman honored for arthritis advocacy – Brainerd Dispatch

February 6th, 2017 9:44 am

For more than 8 years, Sundquist has been learning to manage and overcome juvenile rheumatoid arthritisa diagnosis she received when she was 7 years old, according to a news release. Now, as a young adult, she is becoming an outspoken advocate for the Arthritis Foundation.

As the Arthritis Foundation's signature, national fundraising event, the Walk to Cure Arthritis brings together communities to fight arthritis and is a great way to experience the power of giving back to your community. The local Walk to Cure Arthritis is May 20 at the Paul Bunyan Trailhead in Baxter. For more information, visit http://www.walktocurearthritis.org/northernlakes or call Brekka Nessler at 651-229-5368.

In the United States, more than 50 million adults and 300,000 children live with arthritis and it affects one in five Americans. The Walk to Cure Arthritis will help those living with arthritis by supporting programs, research and advocacy initiatives as well as fund crucial research aimed at finding a cure for the disease.

View original post here:
Local woman honored for arthritis advocacy - Brainerd Dispatch

Read More...

New Synthetic Cartilage Being Used To Treat Common Foot Arthritis – CBS Local

February 6th, 2017 9:44 am

February 3, 2017 6:18 PM

PITTSBURGH (KDKA) Logan Snyder has grown up playing softball, but then her big toes started to bother her.

Once I got to about 12 or 13, says Logan, I started to experience some pain and it just sort of escalated from there.

Her problem: hallux rigidus, or arthritis of the big toes the most common form of arthritis in the foot. The joint degenerates and becomes stiff.

Steps, walking, even just standing became agony.

Aching, almost like a stabbing. Any time the toe would bend, it would hurt. So that was pretty much all the time, Logan said.

Usual measures include shoe inserts, rocker sole shoes, anti-inflammatories, and steroid injections.

Logan had a number of operations to cut away some of the toe bones to relieve pressure, but it didnt help, and she got sick from the pain medicines after surgery.

She sought another opinion from West Penn Hospital foot orthopedist Dr. Victor Prisk, who brought up a new synthetic cartilage.

Its a hydrogel, kind of brings in water. Almost like a contact lens can breathe and bring in water, says Dr. Prisk. Its almost squishy, but firm. It has very similar wear characteristics to our own human cartilage.

It was just approved by the FDA a few months ago. So, Logan was a little hesitant.

Not only is it brand new, but its brand new to him, as well. It was his first one if I remember correctly. So that made me a little nervous, and the fact that it was approved the morning of my surgery, which I didnt know until afterwards, Logan said.

The procedure involves drilling the end of the toe bone and inserting the implant with a special instrument.

The other main surgical option is to fuse the bones together. You gain pain relief, but lose motion.

Using a plug of synthetic cartilage has some advantages.

When they come back in for the two-week post-op visit, they have more motion than they had after any other procedure. And they have more pain relief than with the other procedure, which has been amazing even to me, because I did not expect that, says Dr. Prisk. Its a very fast recovery compared to other procedures. Most people are kind of getting into a shoe within three weeks.

Aside from passive stretching prevent stiffness, there is no required physical therapy.

I had to do it a couple times a day. Just pull it back and like hold it there for as long as I could, which was really rough. But, it was necessary, though, says Logan.

In studies, there is a 4 percent failure rate. The implant was removed because the foot pain persisted, not because there were any problems with the implant. Its not for patients with gout, rheumatoid arthritis certain deformities, or for patients under 18.

It is covered by insurance, but out of pocket, the implant itself runs about $3,500.

I have a lot of movement out of it compared to the previous surgeries, Logan said. Im not quite up to running yet, but walking is still good, going up stairs is good. So, now that I can do that without pain, its just a huge change. Its really nice.

Join The Conversation On The KDKA Facebook Page Stay Up To Date, Follow KDKA On Twitter

Go here to see the original:
New Synthetic Cartilage Being Used To Treat Common Foot Arthritis - CBS Local

Read More...

Fred Lee’s Social Network: Full house for arthritis poker; sipping wine to aid Cambodia children; Year of the … – The Province

February 6th, 2017 9:44 am

Dianne Watts, the MP for South Surrey White Rock, and Liberal MLA hopeful Karen Wang, right, helped usher in the Year of the Rooster at the Bell Centre for Performing Arts. Fred Lee / Postmedia News

John and Nina Cassils once again fronted their eighth annual Taste the World Gala benefiting Cambodias Angkor Childrens Hospital.

After vacationing and falling in love with Myanmar and its people, the couple has rallied others to visit, and created Taste the World to support Cambodias Ankor Childrens Hospital a non-profit pediatrics teaching hospital and the countrys need for better health education and care.

As usual, a raucous crowd filled the Four Seasons Hotel ballroom in Vancouver for the wine and cheese grazer and fundraising event, held in partnership with the Import Vitners and Spirits Association.

Brenda McAllister and Karen Carmichael steered this years tipple fest the first major wine shindig of 2017. Oenophiles sipped and swirled to their hearts content, while bidding on an array of silent and live auction items in support of the worthy cause.

Event emcees Sophie Lui and Brad Jefferson saw for themselves the need to support the effort. Their travel stories to Southeast Asia along with others in the room buoyed the well-heeled crowd to empty their designer purses and wallets of $180,000 and change.

The impressive tally pushed the Cassils humanitarian efforts beyond the $1 million mark. The evenings proceeds will treat some 35,000 children this year who otherwise would not be able to afford health care, says McAllister.

Nina and John Cassils Taste the World event in Vancouver has generated more than $1 million for Cambodias Angkor Childrens Hospital, thanks to the generosity of friends and British Columbians.

Brenda McAllister and Karen Carmichael held the prestigious positions as event co-chairs of the annual Taste the World tipple fest. Their efforts resulted in $180,000 being raised which will help treat some 35,000 patients at the non-profit pediatrics hospital.

Goldcorps David Garofalo escorted his girlfriend Christie King to the wine and cheese grazer at the Four Seasons Hotel in Vancouver. The eighth annual event netted organizers $180,000 for Angkor Childrens Hospital.

Bill Sanford and Danielle Roberts of Appellation Wine offered oenophiles a taste of their Rocca delle Macie wines from Italy and Lake Sonoma wines from California.

After visiting the Angkor Childrens Hospital in Cambodia, Richard and Heidi Coglon were moved to help the children and families there that otherwise could not afford to access basic health care.

The White Rock Chinese Association ushered in the Year of the Rooster at the Bell Performing Arts Centre.

A gala celebration featuring 80 international and local musicians, singers and dancers, the Spring China at White Rock festival sponsored by local developer Landmark Premier Properties benefited the Peace Arch Hospital Foundation and its $15 million ER Campaign.

Several hundred guests, including a gaggle of glad-handing politicos, took in the multicultural arts extravaganza. The yearly party which began in South Surreys Life Church marked its sophomore year at the Bell Centre; a recognition of the growing Chinese community in White Rock and South Surrey.

Yours truly orchestrated the live auction in advance of the two-hour gala performance led by WRCA president Joanne Ding, Landmark PropertiesRaymond Chen and event emcee Lisa Wu.

Auction proceeds contributed to the $18,000 haul. That number quickly rose when Landmark matched every dollar. Not to be outdone, Dave and Rani Mann of Isle of Mann Construction further matched donations.

Before the final curtain fell on the cultural exchange, $72,000 was presented to hospital foundation chair Siobhan Philips and executive director Stephanie Beck.

Stella Chen and Bingqing Lin were among a host of local and international musicians, singers and dancers that performed at the Spring China at White Rock New Year Festival.

Building community, Raymond Chens Landmark Properties sponsored, and Jennifer Dings White Rock Chinese Association produced, the multicultural extravaganza Spring China at White Rock.

Beneficiary of the Chinese New Year party, Peace Arch Hospital Foundation board chair Siobhan Philips and executive director Stephanie Beck collected a $72,000 cheque for its ER Fundraising Campaign.

More than 650,000 British Columbians young and old live with arthritis. And three out of five people are under the age of 65.

The idea that there are more than 100 types of arthritis, and that many can be devastating, debilitating and even fatal, is shocking.

Putting a spotlight on an underestimated, often invisible disease, the B.C. and Yukon chapter of the Arthritis Society presented its inaugural All-in for Arthritis Poker Gala.

Fronted by party chair Dave Turner, tournament chair Sameer Ismailand executive directorChristine Basque, a capacity crowd filled the Stanley Park Pavilion for the charity poker tournament and a chance to play a hand to send kids with arthritis to summer camp.

Celebrating its 35th year, the Arthritis Camp provides a unique opportunity for children to meet others who understand what its like to grow up with the disorder.

Keynote speakerAdrienne Dalla-Longa knows first hand the magic of the camp. Diagnosed with juvenile arthritis, she had to wear ankle, knee and wrist braces in school, and was prevented from participating in many activities.

Bullied by peers who did not understand why she was unable to play, the camp introduced her to others with shared challenges and highlighted she was not alone in her journey. Dalla-Longas compelling story helped table $85,000 for the society.

Rheumatologist Dr. Jean Gillies was all-in for Samantha Rogers poker charity tournament. The inaugural event raised $85,000 for the Arthritis Societys B.C. and Yukon chapter.

Arthritis ambassador Adrienne Dalla-Longa joined Arthritis Society executive director Christine Basque and gala emcee Dawn Chubai for all the fun and games at the Stanley Park Pavilion.

Tournament chair Sameer Ismail congratulated Clark Wilsons Ryan Tam, the inaugural winner of the Arthritis Societys All-In for Kids Poker Championship. Monies will go toward sending children with arthritis to summer camp.

Drew McArthur, past chair of the national board of The Arthritis Society, and his wife Heather, helped mark the 35th anniversary of the arthritis kids camp, a summer program that gives children with arthritis the chance to meet others who live with similar challenges and to make lasting memories.

CLICK HERE to report a typo.

Is there more to this story? Wed like to hear from you about this or any other stories you think we should know about. Email vantips@postmedia.com

See the original post:
Fred Lee's Social Network: Full house for arthritis poker; sipping wine to aid Cambodia children; Year of the ... - The Province

Read More...

Taking on Arthritis: 3 Unique Ideas for Pain Relief – Care2.com

February 6th, 2017 9:44 am

Few people escape the daily aches and pains that come with aging. But persistent joint pain and stiffness can be a sign of something more: arthritis.

Arthritis affects more than 50 million adults and 300,000 children, according tothe Arthritis Foundation, making it the most common cause of disabilityin America. Maybe you know a parent or grandparent who suffers from arthritis; ormaybe you deal with it yourself.

There are two types of arthritis: rheumatoid arthritis, which is an inflammatory disease, and osteoarthritis, a type that is caused by the wearing away of joint cartillage. Either way, the most common symptom is pain and stiffness around the joints knees, hips, hands, etc.

Most people who suffer from arthritis turn to solutions like pain medications and stretching exercises to find relief. However, there are a number of other natural ways to soothe arthritis pain!

Here are a few oddball ideas you may not have heard of before.

3 Unique Ideas for Arthritis Pain Relief

Drink White Willow Tea

Before there was aspirin, white willow tea was the pain killer of choice. In fact, this remedy stretches all the way back to Hippocrates, a Greek physician who was operating back in 5th century BC!

White willow contains an active ingredient called salicin, a chemical that is converted in the body into salicylic acid. Sound familiar? Its essentially a less irritating form of acetyl salicylic acid, theactive ingredient in aspirin.

How to Make White Willow Tea:

Massage Sore Joints with Olive Oil

Extra virgin olive oil (sometimes abbreviated to EVOO)has anti-inflammatory properties that can actually inhibit inflammation just like aspirin or Advil.

To soothe your joints, gently massage a bit of cold-pressed, extra virgin olive oil into your sore joints, twice daily or more. You can also take a spoonful or two internally to reap its benefits as a reducer of swelling.

Related: 4 Myths About Olive Oil Debunked

Enjoy Turmeric-Based Foods

Turmeric(an earthy yellow spice you may recognize from Indian and East Asian dishes) is well-known for its anti-inflammatory properties. Its active ingredient is a naturally-occurring chemical called curcumin, which is a powerful antioxidant that lowers the levels of the enzymes responsible for causing inflammation.

There are several ways to enjoy turmeric, so stock up on those recipes; however, the simplest way to enjoy its benefits is through delicious golden milk or a lovely turmeric and ginger tea.

How to Make Turmeric & Ginger Tea:

Arthritis is a challenging, painful disease that can be hard to manage, but you dont have to suffer without aid. Test these three natural remedies throughout your day and trust what works. You may just find the relief youve been looking for.

How do you manage arthritis in your body? Do you have any tips that may help someone else find relief?

Disclaimer: The views expressed above are solely those of the author and may not reflect those of Care2, Inc., its employees or advertisers.

View original post here:
Taking on Arthritis: 3 Unique Ideas for Pain Relief - Care2.com

Read More...

Drug combination effective against chikungunya arthritis in mice … – Science Daily

February 6th, 2017 9:44 am

Combining a drug for rheumatoid arthritis with one that targets the chikungunya virus can eliminate the signs of chikungunya arthritis in mice in the disease's earliest stage, according to researchers at Washington University School of Medicine in St. Louis.

The findings could lead to a drug therapy for the painful, debilitating condition for which there currently is no treatment.

"We found that combining these two drugs could abolish the signs of arthritis in mice during the acute phase," said Deborah Lenschow, MD, PhD, an associate professor of medicine and the study's co-senior author, referring to the phase in the first weeks after infection.

The study is published Feb. 1 in Science Translational Medicine.

Until about a decade ago, chikungunya virus, which is transmitted by mosquitoes, mainly was restricted to East Africa and South Asia. But in recent years the virus has spread around the world. The first case originating in the Western Hemisphere was reported in late 2013, and by the end of 2015, the virus had infected an estimated 1.8 million people in the Americas.

Chikungunya infection causes fever and severe joint pain, as well as rash, muscle pain and fatigue. The majority of patients continue to experience joint pain six months after infection, and for some, the arthritis continues for years.

"We were seeing people at our rheumatology clinic whose signs and symptoms really mimicked rheumatoid arthritis but who had been infected with chikungunya," Lenschow said. "This raised the question in our minds, 'Would therapeutics we use to treat rheumatoid arthritis be of any benefit to patients with chikungunya arthritis?'"

To find out, Lenschow, co-senior author Michael Diamond, MD, PhD, and colleagues tested a panel of six rheumatoid arthritis drugs -- all approved by the Food and Drug Administration for use in patients -- on mice infected with chikungunya virus.

All six drugs work by suppressing the activity of the immune system. Although different in many ways, rheumatoid arthritis and chikungunya arthritis both involve out-of-control immune activity in the joints.

The researchers injected seven groups of mice with the virus and three days later administered one of the six arthritis drugs or a placebo to each group of mice. A week after infection -- when the mice's arthritis signs were at their peak -- the researchers measured the amount of swelling around the joints as well as the numbers of immune cells and molecules in the affected areas.

Two of the drugs -- abatacept and tofacitinib -- significantly reduced the swelling and the levels of immune cells and molecules. Importantly, the levels of live virus did not increase in the animals given the immunosuppressive arthritis drugs.

"There was a significant concern that administering any immunosuppressive drug would allow the virus to escape from immune control, leading to worse outcomes in the long term," said Diamond, the Herbert S. Gasser Professor of Medicine. "We've seen that with other viruses, but in this case, none of the drugs seemed to exacerbate viral replication. This raises the possibility that these drugs can be safely investigated in humans."

The treatment was only partially successful at resolving the arthritis, however, which led the researchers to test whether adding a human antibody against chikungunya virus could improve the effectiveness.

As before, the researchers infected mice with the virus and three days later dosed them with the arthritis drug abatacept, the antiviral drug or both. Each drug individually reduced joint swelling a week after infection. But when abatacept and the antiviral drug were used together, the joint swelling and the infectious virus in the animals' joints were eliminated.

"We saw real improvement in the acute phase, but unfortunately, the drug interventions we tried failed to correct the chronic phase," Diamond said.

In humans, the chronic phase of chikungunya arthritis starts three weeks after initial infection and lasts as long as the patient continues to experience joint pain, which can be three or four years. During the chronic phase, infectious virus is no longer detectable in the joints, but viral genetic material persists and may be sufficient to trigger an ongoing immune response, causing the tissue damage that patients perceive as arthritis.

The researchers found a similar pattern in the mice treated with the drug combination: By four weeks after infection, live virus was no longer present in the animals' joints, but viral genetic material remained, suggesting that the drugs had not eliminated the chronic phase of the disease.

It is possible that a treatment that reduces arthritis symptoms in the first weeks after infection could lower the chance that the disease becomes chronic, but no data has yet been published for or against the possibility. Still, any effective treatment, even if short-lived, would be a boon for chikungunya patients, who currently have no proven treatment options. Lenschow has discussed beginning a human study with colleagues in Brazil, but plans are not yet finalized.

"In those first weeks, people are really very sick with a high fever and a lot of pain, so if further studies show that this combination treatment is effective in humans, that will have real benefits for patients," Diamond said. "As for the chronic phase, we're going to continue looking for other treatment strategies."

Continue reading here:
Drug combination effective against chikungunya arthritis in mice ... - Science Daily

Read More...

Discovery of new T-cell subtype opens window on rheumatoid … – Science Daily

February 6th, 2017 9:44 am

A research team led by scientists from Brigham and Women's Hospital (BWH) has carefully scrutinized the immune cells from patients with rheumatoid arthritis, revealing a striking new subset of T-cells that collaborate with other immune cells to drive inflammation in peripheral tissues. The work, which was propelled by technologies that enable the detailed analysis of even a handful of cells, opens a critical window on the biology of the disease and suggests a strategy for the development of more precise, powerful treatments. The study appears in the February 1st advance online edition of the journal Nature.

"While the newest therapies for rheumatoid arthritis have helped transform our ability to treat the disease, they are fairly blunt instruments -- blocking components of the immune system in a non-specific, global way," said first author Deepak Rao, who co-directs the Human Immunology Center at BWH. "Our results help illuminate a path toward treatments that are much more precise and focused only on the most relevant immune cells."

Rheumatoid arthritis is an autoimmune condition in which the immune system attacks the joints, causing inflammation, pain, and eventually destruction of the tissues that make up this essential body part. The disorder affects roughly 1 percent of the world's population, and disproportionately afflicts women. Although there is significant evidence implicating T-cells -- particularly their interactions with B-cells, which produce antibodies -- it has been unclear which T-cell subtypes help orchestrate the damaging immune responses that underlie rheumatoid arthritis.

Rao, together with senior author Michael Brenner, set out to explore these questions by studying patient samples in remarkable detail not achieved in earlier studies. This "disease deconstruction" approach relies on sophisticated technologies, such as mass cytometry, which allowed the researchers to rapidly sift through blood, joint tissue, and the fluid surrounding joints to isolate specific cells, defined by the assortment of molecules on their surfaces. Rao and his colleagues also harnessed RNA sequencing methods that can characterize even very small numbers of cells, revealing which genes are turned on or off.

By using these and other high-tech tools, the researchers homed in on a unique population of T-cells that are highly prevalent in the joints of rheumatoid arthritis patients. These cells, a kind of CD4+ or "helper" T-cell, represent roughly one-quarter of the helper T-cells found in patients' joints. Yet abundance is not their only noteworthy attribute.

"These cells don't adhere to the conventional view of helper T-cells, and that is really interesting," said Rao.

By taking a deep look at these unique helper T-cells, Rao and his colleagues discovered that they display some unusual biological features. These T-cells are programmed to infiltrate parts of the body that are inflamed, and there they stimulate B-cells to produce antibodies. Antibodies are specialized proteins that usually recognize foreign substances and help rally the immune system to eliminate them. In autoimmune diseases, so-called autoantibodies instead recognize normal components of the human body and contribute to tissue damage. The Nature study represents the first detailed description of a type of T-cell with these features.

To extend their initial findings, the researchers seek to understand the signals that coax these cells to develop, and whether they play roles in other autoimmune diseases, such as lupus, multiple sclerosis, and type 1 diabetes. The BWH team also plans to explore whether targeting these unique T-cells hold promise as a treatment for rheumatoid arthritis.

"This work is a remarkable illustration of the power of our disease deconstruction approach," said Brenner, who also directs BWH's Human Immunology Center together with Rao. "We hope it will prove equally illuminating as we apply it to other immune-mediated diseases."

Story Source:

Materials provided by Brigham and Women's Hospital. Note: Content may be edited for style and length.

Read the rest here:
Discovery of new T-cell subtype opens window on rheumatoid ... - Science Daily

Read More...

Stem Cell Therapy Helps North Texas Teen Beat Asthma | NBC 5 … – NBC 5 Dallas-Fort Worth

February 6th, 2017 9:43 am

A North Texas teenager who battled severe asthma for years is breathing free and clear again after doctors used stem cell therapy to temporarily treat his condition. (Published Monday, Jan. 30, 2017)

A North Texas teenager who battled severe asthma for years is breathing free and clear again after doctors used stem cell therapy to temporarily treat his condition.

Kenton Crenshaw, 18, of Crowley, never knew when his asthma would strike.

"Like 2, 3, 4 in the morning and it just hits me and I freak out," Crenshaw said.

"My asthma stopped me from doing lots of stuff that I wanted to do," he added.

Activity, even as light as walking outside, came with risk.

"I spent eight Christmases in the hospital because of asthma days or weeks long, birthdays it's just controlled my life," he said.

Crenshaw took countless medications but nothing seemed to help, so his family brought him to Dr. Bill Johnson at Innovations Medical in Dallas.

Johnson is one of a growing group of doctors using stem cell therapy to treat various diseases.

"The stem cells have the ability to reproduce and become other types of tissue, and that's what makes them so special," Johnson said.

Johnson took a small amount of fat from the Crenshaw through liposuction and separated the stem cells in a centrifuge.

He then mixes the stem cells with a solution, which is given back to patients, like Crenshaw, through intravenous therapy or breathing treatments.

"He has an overactive immune system with his lungs and airways, and what the stem cells can do is turn that down, decrease inflammation, and he's had a remarkable course," Johnson said, of Crenshaw.

It's been a few months since the treatments, and Crenshaw says he hasn't needed many of his medications.

"I felt like I never had asthma, like I feel perfect. I didn't do one breathing treatment in almost three months and I used to do four to six breathing treatments a day," he said.

The treatment isn't said to cure his asthma, but the results can last a year possible longer.

"I hope I never have an asthma attack the rest of my life," Crenshaw said.

Stem cell therapy treatments cost upwards of $7,000 and are not covered by insurance.

Published at 10:03 PM CST on Jan 30, 2017 | Updated at 10:41 PM CST on Jan 30, 2017

Originally posted here:
Stem Cell Therapy Helps North Texas Teen Beat Asthma | NBC 5 ... - NBC 5 Dallas-Fort Worth

Read More...

Experimental Stem Cell Therapy Stops Multiple Sclerosis In Its … – Vocativ

February 6th, 2017 9:43 am

The prognosis for people affected by multiple sclerosis (MS), a degenerative autoimmune disorder that decimates the central nervous system, is a bleak one. The disease oftenbegins with a sudden burst of neurological symptoms like muscle spasms, vision problems, and trouble walking, then progresses differently, depending on which form of MS someone has. But eventually, nearly everyone with the disease comesto the point of being unable to move, breathe, or live independently. And sufferers on average live anywhere from five to ten years less than the general public.

Currently, the best medications we have available do little more than slow MS down, or tamp down peoples symptoms. But an experimental therapy continues to provide the first glimmers of something ground-breaking an actual way to stop one form of the disease in its tracks, and maybe even reverse some of the damage already done.

In this months Neurology, researchers detailed the final five-year-old results of a small clinical trial called HALT-MS. Twenty-four volunteers with MS who hadnt responded to conventional drugs were first given a powerful form of chemotherapy, high-dose immunosuppressive therapy (HDIT), that wiped out their immune system. Then they were given a transplant of their own stem cells taken out earlier, known as autologous hematopoietic cell transplant (HCT). These purified cells, the researchers theorized, would seed a new generation of uncorrupted white blood cells and reset the immune system, freezing MS in its place.

For the most part thats exactly what the combination HDIT/HCT therapy did. Nearly 70 percent of patients, five years in, have experienced no signs of the disease progressing. They havent had a relapse of symptoms, become more disabled, or had new brain lesions show up in imaging exams. Some have actually improved physically in the years since the treatment. And even those not in complete remission appear to be suffering less than before. Importantly, though the treatment isnt free of side-effects, there havent been severe ones. There were three deaths seen during the trial, all of whom experienced worsening MS, but none were attributed to the treatment.

The volunteers all had relapsing-remitting MS, the most common form, in which symptoms come and go with little rhyme or reason.

The evidence at this time is encouraging, but it isnt definitive, study author Dr. Linda Griffith, a researcher at the National Institute of Allergy and Infectious Diseases (NIAID), which sponsored the study, told Vocativ.

As Vocativ has previously reported, this isnt the first trial to find similar success rates for HDIT/HCT, though it does come with its own dangers. Patients can die from it, and like all kinds of chemotherapy, the deliberate weakening of the immune system often leads to more infections. It also doesnt seem to be as effective for more advanced types of MS, when the disease has stopped causing active inflammation, said Griffith. And while it could be promising for people in the earliest stages of MS, the research needed to promote it as a first-line treatment isnt there yet either, she added.

For now, the only trials of HDIT/HCT have been small and isolated. And though the effects of it when successful seem to extend as far out as 13 years later, its too early to call it a full-on cure. We still dont have a clear grasp of why MS happens in the first place, but its thought that multiple triggers like infections and unlucky genetics combine to increase peoples risk. So even if resetting someones immune system does treat MS completely, its plausible that some percentage of patients could fall victim to it again down the road, Griffith explained. We just dont know enough right now.

But Griffith is hopeful that larger, randomized studies will be underway within the next year or so. And if those prove to be as successful as the HALT-MS trial and others, the therapy could someday soon lead to a light at the end of tunnel for the millions of MS sufferers alive today.

Excerpt from:
Experimental Stem Cell Therapy Stops Multiple Sclerosis In Its ... - Vocativ

Read More...

Stem Cell Therapy Offers Hope to Multiple Sclerosis Patients (VIDEO) – Newsy

February 6th, 2017 9:43 am

ByEthan Weston February 2, 2017

Stem cell research is making medical breakthroughs, and now, it could offer hope to people who have multiple sclerosis.

A newNational Institutes of Healthstudy suggests one-time stem cell transplants might be more effective than long-term medicinal treatment at treating relapsing-remitting MS.

Multiple sclerosis is an autoimmune disease that causes a person's immune system to attack their central nervous system. Common symptoms are impaired motor function, weakness and chronic pain. Relapsing-remitting MS is the most common form of the disease.

Stem cells are cells that haven't decided what they want to be when they grow up. That means they can develop into different types of cells. Because of that, they can be used to heal older damaged cells, like those attacked by the immune system.

The study followed 24 people who weren't having success with the typical MS medications. The experimental treatment suppressed participants' immune systems with chemotherapy. Then, their own stem cells were transplanted back into their bodies to rebuild their immune systems.

Related StoryPart-Pig, Part-Human Embryos Could Give Us Replacement Human Organs

Five years after treatment, most participants' symptoms were in remission. Some of them even showed some improvements.

Larger studies will be needed to confirm these findings. But the head of the study said it's a good first step toward more effective treatment for an incredibly debilitating and deadly disease.

Read the rest here:
Stem Cell Therapy Offers Hope to Multiple Sclerosis Patients (VIDEO) - Newsy

Read More...

From Down syndrome to ‘near normal’? New Delhi clinic makes stem cell claims that worry experts – National Post

February 6th, 2017 9:43 am

A New Delhi clinic that has claimed to help paralyzed Canadians walk again by injecting them with stem cells now says it can use the same treatment to make children with Down syndrome almost near normal.

Nutech Mediworld says it has treated up to 16 newborns, toddlers and older children with Down syndrome. According to its medical director, Geeta Shroff, we have seen that patients actually start improving clinically they become almost at par for their age.

Canadian experts say the bold claim risks raising false expectations and public confusion, much like the now-discredited Liberation therapy for multiple sclerosis, and that its playing off the over-hyped belief stem cells have the potential to cure almost anything.

Its also the latest controversy over stem cell tourism, and the growing number of clinics worldwide marketing pricey, unregulated and unproven treatments.

Nutech Mediworld charges US$5,000 to $6,000 per week for its stem cell-based therapies. The clinic says it has treated such incurable conditions as spinal cord injury and cerebral palsy. Around 20 Canadians have sought treatment at the clinic for paralyzing spinal cord injuries, spending upwards of $US48,000 each. Shroff says some of her patients have regained the ability to walk with walkers.

More recently, she began working with Down syndrome, one of the most common chromosomal disorders worldwide.

Most cases are caused by a random error in cell division. The child ends up with three copies of chromosome 21, instead of the usual two.

That extra copy causes abnormal neuronal development and changes in the central nervous system, Shroff says, leading to persistent developmental delays.

Human embryonic stem cells injected into a childs muscles and bloodstreamcan regenerate and repair that damaged brain, she says. They also work at the genetic level, she claims.

In a single case published last year, Shroff reported treating a two-month-old baby boy in September 2014 diagnosed with Down syndrome at birth. The infant had delayed milestones, lack of speech, subnormal understanding and subnormal motor skills, she wrote.

After two stem cell therapy sessions, the baby started babbling and crawling, she reported. He had improved muscle tone. He was social and was able to recognize near ones.

The child became almost as near normal as possible cognitively

The child became almost as near normal as possible cognitively, Shroff told the Post in an interview. Today, hes talking; hes walking. He was at par with normal children on analysis.

The former infertility specialist uses embryonic stem cells developed from a single fertilized egg donated by an IVF patient 17 years ago. According to Shroff, We have witnessed no adverse events at all.

The Down syndrome treatments, reported by New Scientist, have raised skepticism and alarm. Its not at all clear what cells shes actually putting in patients, says renowned developmental biologist Janet Rossant, senior scientist at the Hospital for Sick Children Research Institute in Toronto.

By just putting them into the bloodstream theres no way to imagine they could contribute to the right tissues.

Embryonic stem cells can also form teratomas benign tumours and masses composed of lung cells, tufts of hair, teeth, bone and other tissues.

The gold standard for any therapy would be a clinical trial comparing treated with untreated children and vetted through proper regulatory systems that clearly she is not going through, Rossant says.

The Ottawa Hospitals Dr. Duncan Stewart, who is leading the first trial in the world of a genetically enhanced stem cell therapy for heart attack, says theres a remote chance embryonic stem cells could help with Down syndrome. But its a stretch. The injected cells would also likely be rejected and die off with days, he believes. If the cells are disappearing within days, how are they working?

This is a very vulnerable population Theyre very vulnerable to people who are selling hope and have no basis for it

This is a very vulnerable population, Stewart adds. Theyre very vulnerable to people who are selling hope and have no basis for it.

But stem cells have taken on almost mystical appeal.

Theyve become a pop culture phenomenon, says healthy policy expert Timothy Caulfield, of the University of Alberta. The field itself is guilty of making breathless announcements about breakthroughs and cutting edge, he says. And people can market that kind of language.

This kind of nonsense doesnt help.

Email: jskirkey@postmedia.com | Twitter:

Continued here:
From Down syndrome to 'near normal'? New Delhi clinic makes stem cell claims that worry experts - National Post

Read More...

Mesenchymal stem cells: the ‘other’ bone marrow stem cells …

February 5th, 2017 3:45 am

No treatments using MSCs are yet available. However, several possibilities for their use in the clinic are currently being explored.

Bone and cartilage repair The ability of MSCs to differentiate into bone cells called osteoblasts has led to their use in early clinical trials investigating the safety of potential bone repair methods. These studies are looking at possible treatments for localized skeletal defects (damage at a particular place in the bone).

Other research is focussed on using MSCs to repair cartilage. Cartilage covers the ends of bones and allows one bone to slide over another at the joints. It can be damaged by a sudden injury like a fall, or over a long period by a condition like osteoarthritis, a very painful disease of the joints. Cartilage does not repair itself well after damage. The best treatment available for severe cartilage damage is surgery to replace the damaged joint with an artificial one. Because MSCs can differentiate into cartilage cells called chondrocytes, scientists hope MSCs could be injected into patients to repair and maintain the cartilage in their joints. Researchers are also investigating the possibility that transplanted MSCs may release substances that will tell the patients own cells to repair the damage.

Many hurdles remain before this kind of treatment can become a reality. For example, when MSCs are transplanted, most of them are rapidly removed from the body. Researchers are working on new techniques for transplanting the cells, such as developing three-dimensional structures or scaffolds that mimic the conditions in the part of the body where the cells are needed. These scaffolds will hold the cells and encourage them to differentiate into the desired cell type.

Heart and blood vessel repair Some studies in mice suggest that MSCs can promote formation of new blood vessels in a process called neovascularisation. MSCs do not make new blood vessel cells themselves, but they may help with neovascularisation in a number of ways. For example, they may release proteins that stimulate the growth of other cells called endothelial precursors cells that will develop to form the inner layer of blood vessels. They may also "guide" the assembly of new blood vessels from preexisting endothelial cells (those that line the blood vessel). Such studies on animals have led researchers to hope that MSCs may provide a way to repair the blood vessel damage linked to heart attacks or diseases such as critical limb ischaemia. A number of early stage clinical trials using MSCs in patients are currently underway but it is not yet clear whether the treatments will be effective.

Inflammatory and autoimmune diseases Several claims have been made that MSCs are able to avoid detection by the immune system and can be transplanted from one patient to another without risk of immune rejection by the body. However, these claims have not been confirmed by other studies. MSCs are rejected like any other "non-self" cell type. It has also been suggested that MSCs may be able to slow down the multiplication of immune cells in the body to reduce inflammation and help treat transplant rejection or autoimmune diseases. Again, this has yet to be proven and much more evidence is needed to establish whether MSCs could really be used for this kind of application.

Follow this link:
Mesenchymal stem cells: the 'other' bone marrow stem cells ...

Read More...

Page 1,078«..1020..1,0771,0781,0791,080..1,0901,100..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick